Vaxcyte Inc
1PCVX
Company Profile
Business description
Vaxcyte Inc is a clinical-stage vaccine innovation company engineering high-fidelity vaccines to protect humankind from the consequences of bacterial diseases. It is developing broad-spectrum conjugate and novel protein vaccines to prevent or treat bacterial infectious diseases. Its product comprises of Pneumococcal conjugate vaccine. The firm's product candidate consists of VAX-31, VAX-24, VAX-A1, VAX-PG, VAX-GI, and Others.
Contact
825 Industrial Road
Suite 300
San CarlosCA94070
USAT: +1 650 837-0111
Sector
Healthcare
Stock type
Defensive
Industry
Biotechnology
Fiscal Year End
31 December 2025
Employees
414
Stocks News & Analysis
stocks
Coca-Cola earnings: Innovation and brand strength underpin growth
We plan to raise our fair value estimate of Coca-Cola stock.
stocks
Going into earnings, is Netflix stock a buy, a sell, or fairly valued?
Watching sales growth and the potential for margin expansion, here’s what we think of Netflix stock.
Morningstar Investment Ideas
Markets
Index | Last price | Change | % Change |
|---|---|---|---|
| All Ordinaries | 9,390.10 | 16.40 | 0.17% |
| CAC 40 | 8,258.86 | 52.79 | 0.64% |
| DAX 40 | 24,330.03 | 71.23 | 0.29% |
| Dow JONES (US) | 46,983.28 | 276.70 | 0.59% |
| FTSE 100 | 9,426.99 | 23.42 | 0.25% |
| HKSE | 26,027.55 | 168.72 | 0.65% |
| NASDAQ | 22,973.00 | 17.54 | -0.08% |
| Nikkei 225 | 49,316.06 | 130.56 | 0.27% |
| NZX 50 Index | 13,377.85 | 32.89 | 0.25% |
| S&P 500 | 6,742.37 | 7.24 | 0.11% |
| S&P/ASX 200 | 9,094.70 | 18.80 | 0.21% |
| SSE Composite Index | 3,916.33 | 52.44 | 1.36% |